Gilead has posted early data on a first-in-class inhibitor of HIV-1 capsid function it thinks could play a role in long-acting combination therapies. The data supported the progress of the asset, GS-6207, into a phase 1b trial in HIV-1 infected adults.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,